- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: Encorafenib
Total 81 results
-
Copenhagen Studies on Asthma in ChildhoodActive, not recruitingAsthma | Allergy | EczemaDenmark
-
Pierre Fabre MedicamentPfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. LtdCompletedBRAF V600E-mutant Metastatic Colorectal CancerFrance, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
-
Pierre Fabre MedicamentMerck KGaA, Darmstadt, GermanyActive, not recruitingMetastatic Colorectal Cancer | BRAF V600EChina
-
PfizerMerck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd; Pierre Fabre MedicamentCompletedBRAF V600E-mutant Metastatic Colorectal CancerUnited States, Spain, Korea, Republic of, United Kingdom, Australia, Czechia, Taiwan, Belgium, France, Hungary, Canada, Japan, Russian Federation, Netherlands, Israel, Germany, Turkey, Austria, Brazil, Poland, Italy, Argentina, Chile, Denmar... and more
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingMelanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Metastatic Malignant Neoplasm in Lymph NodeUnited States
-
Craig L Slingluff, JrNational Cancer Institute (NCI)Terminated
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Metastatic Malignant Neoplasm in the Brain | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
-
Pierre Fabre MedicamentEuropean Organisation for Research and Treatment of Cancer - EORTCActive, not recruitingMelanomaSpain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
-
European Organisation for Research and Treatment...Active, not recruitingStage IV Melanoma | Unresectable Stage III MelanomaFrance, Denmark, Spain, Finland, Italy, Germany, Poland, United Kingdom, Netherlands
-
Pierre Fabre MedicamentActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterArray BioPharmaCompletedAdvanced BRAF Mutant CancersUnited States
-
PfizerCompletedHepatic ImpairmentUnited States
-
Grupo Español Multidisciplinar de MelanomaPierre Fabre Medicament; MFARActive, not recruitingMetastatic Melanoma | Brain MetastasesSpain
-
PfizerPierre Fabre LaboratoriesActive, not recruitingAdvanced Solid Tumors | Metastatic MelanomaUnited States, Spain, Belgium, Canada, Netherlands
-
PfizerTerminatedBrain MetastasesUnited States, Belgium, Australia, Argentina, Italy
-
Peter MacCallum Cancer Centre, AustraliaTerminated
-
Novartis PharmaceuticalsTerminated
-
Novartis PharmaceuticalsCompletedBRAF v600 Mutated Metastatic MelanomaUnited States
-
Novartis PharmaceuticalsCompleted
-
PfizerPierre Fabre LaboratoriesTerminated
-
Pierre Fabre MedicamentWithdrawnHepatic Impairment | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 MutationSpain, Czechia, Italy
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Eli Lilly and CompanyCompletedColorectal Cancer | Metastatic Melanoma | Advanced Cancer | Metastatic Non-small Cell Lung CancerUnited States, Japan, Australia, France
-
Pierre Fabre MedicamentCompletedMelanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLCChina
-
University of Heidelberg Medical CenterGerman Cancer Research Center; University Hospital Heidelberg; Array BioPharma; Coordinating Centre for Clinical Trials HeidelbergActive, not recruitingRelapsed or Refractory Multiple Myeloma | Patients With BRAFV600 E or BRAFV600K MutationGermany
-
Bristol-Myers SquibbCompletedHealthy ParticipantsUnited States
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID) | Immune Thrombocytopenic Purpura (ITP) | Kawasaki SyndromeUnited States
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)United States
-
Prof. Dr. med. Dirk SchadendorfCompleted
-
Array BioPharmaTerminatedMelanomaCanada, Spain, Australia, Switzerland, Germany, United States
-
Array BioPharmaTerminatedLocally Advanced Metastatic BRAF Mutant MelanomaAustralia, Canada, Netherlands, United States